Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 9;22(20):10918.
doi: 10.3390/ijms222010918.

Primary Immune Thrombocytopenia and Essential Thrombocythemia: So Different and yet Somehow Similar-Cases Series and a Review of the Literature

Marta Sobas  1 , Maria Podolak-Dawidziak  1 , Krzysztof Lewandowski  2 , Michał Bator  1 , Tomasz Wróbel  1
Affiliations
Review

Primary Immune Thrombocytopenia and Essential Thrombocythemia: So Different and yet Somehow Similar-Cases Series and a Review of the Literature

Marta Sobas et al. Int J Mol Sci. .

Abstract

This article collects several published cases in which immune thrombocytopenic purpura (ITP) is followed by essential thrombocythemia (ET) and vice versa. This surprising clinical condition is possible, but very rare and difficult to diagnose and manage. We have made an attempt to analyse the possible causes of the sequential appearance of ITP and ET taking into consideration the following: alteration of the thrombopoietin (TPO) receptor, the role of autoimmunity and inflammation, and cytokine modulation. A better understanding of these interactions may provide opportunities to determine predisposing factors and aid in finding new treatment modalities both for ITP and ET patients.

Keywords: essential thrombocythemia; immune thrombocytopenic purpura; platelet oscillation.

PubMed Disclaimer

Conflict of interest statement

M.S. has received honoraria fees for lectures for Novartis and serving on advisory boards from Novartis and Celgene. M.P.-D. has received honoraria lectures, chairing sessions, and serving on advisory boards from Amgen, CSL Behring, Novartis, Orphan, Sanofi, Roche, Takeda. K.L. has received honoraria fees for lectures, chairing sessions, and serving on advisory boards from Novartis and AbbVie. M.B. does not declare conflict of interest. T.W. has research grant from Roche, advisory board: Roche, Novartis, Abbvie, Gilead, BMS, Janssen-Cilag, Celgene and received honoraria fees from Roche, Novartis, Abbvie, Gilead, BMS, Janssen-Cilag, Alexion and Amgen.

References

    1. Huang C.-E., Chen Y.-Y., Liu J.-L., Ho H.-Y., Li C.-P., Chen C.-C. JAK2V617F Mutation in Immune Thrombocytopenia. Thromb. Res. 2016;144:149–151. doi: 10.1016/j.thromres.2016.06.019. - DOI - PubMed
    1. Sobas M.A., Wróbel T., Zduniak K., Podolak-Dawidziak M., Rybka J., Biedroń M., Sawicki M., Dybko J., Kuliczkowski K. Immune Thrombocytopenia and JAK2V617F Positive Essential Thrombocythemia: Literature Review and Case Report. Case Rep. Hematol. 2017;2017:3725089. doi: 10.1155/2017/3725089. - DOI - PMC - PubMed
    1. Caocci G., Atzeni S., Usai M., La Nasa G. Essential Thrombocytemia Following Immune Thrombocytopenia with JAK2V617F Mutation. Leuk. Res. Rep. 2018;9:14–15. doi: 10.1016/j.lrr.2017.12.002. - DOI - PMC - PubMed
    1. Barrett A., Cahill M.R. CALR-Positive Essential Thrombocythaemia Preceded by Immune Thrombocytopaenia. Ir. Med. J. 2021;114:1–4.
    1. Marisabel H.-C., Brian F., Morris J. Immune Thrombocytopenic Purpura with Subsequent Development of JAK2 V617F-Positive Essential Thrombocythemia: Case Report. Arch. Hematol. Case Rep. Rev. 2021;6:018–020. doi: 10.17352/ahcrr.000033. - DOI

MeSH terms

LinkOut - more resources